Bladder tumor organoid, culture method and application thereof

By optimizing the culture medium and environment for bladder tumor organoids, and utilizing Advanced DMEM/F-12 basal medium and ultra-low adsorption cell culture plates, the problems of slow culture speed and large passage damage of bladder tumor organoids were solved, achieving rapid prototyping and stable passage, and improving culture efficiency and the activity of tumor organoids.

CN119639673BActive Publication Date: 2025-10-28CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411533662.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-10-31
Publication Date
2025-10-28
Estimated Expiration
2044-10-31

AI Technical Summary

Technical Problem

In existing technologies, the culture speed of bladder tumor organoids is slow, making it difficult to form them in a short period of time. Furthermore, the passage process causes significant damage, affecting the activity and proliferative capacity of the tumor organoids.

Method used

Using Advanced DMEM/F-12 as the base medium, supplemented with HEPES buffer, penicillin-streptomycin solution, GlutaMAX, B-27 additive, N-acetylcysteine, nicotinamide, SB202190, A83-01, Y-27632, recombinant human Rspo1 protein, recombinant human cephaloprotein, recombinant human fibroblast growth factor-10, recombinant human fibroblast growth factor-2, human epidermal growth factor, and matrix gel, combined with ultra-low adsorption cell culture plates, the culture conditions were optimized to achieve rapid prototyping and stable passage.

Benefits of technology

It enables the formation of bladder tumor organoids within 24 hours and the acquisition of primary cultured organoids within 72 hours, improving the success rate of culture, reducing the use of cytokines, and is easy to operate and applicable to commonly used organoid culture conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005111014790000061
    Figure BDA0005111014790000061
  • Figure BDA0005111014790000071
    Figure BDA0005111014790000071
  • Figure BDA0005111014790000111
    Figure BDA0005111014790000111
Patent Text Reader

Abstract

This invention provides a bladder tumor organoid, its culture method, and its applications, belonging to the field of organoid culture technology. The invention involves mixing bladder tumor tissue with a human bladder tumor organoid culture medium to obtain a cell suspension. This cell suspension is then cultured in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids. This culture method utilizes an ultra-low adsorption cell culture plate, enabling the suspension culture of bladder tumor organoids in a liquid culture medium. The culture method described in this invention achieves rapid culture of human bladder tumor organoids, improving the culture success rate. Furthermore, the obtained human bladder tumor organoids can be digested and stably passaged.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of organoid culture technology, and particularly relates to a bladder tumor organoid, its culture method, and its application. Background Art

[0002] Bladder cancer generally refers to urothelial carcinoma occurring in the bladder. It is the most common cancer of the urinary system and is a highly heterogeneous malignant tumor. Pathologically, it can be divided into two main types: non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Approximately 70% of bladder cancer patients present with non-muscle-invasive bladder cancer; the proportion is even higher in younger patients (<40 years old). Regarding muscle-invasive bladder cancer, although smoking is the most clearly defined risk factor, increasing evidence suggests that genetic susceptibility and family history may contribute to its development. In terms of treatment, non-muscle-invasive tumors require intravesical chemotherapy after surgery, and a significant proportion of patients experience tumor recurrence during treatment. Patients with muscle-invasive tumors require a certain number of cycles of neoadjuvant chemotherapy before radical cystectomy, but some patients do not benefit from neoadjuvant chemotherapy.

[0003] Organoids are miniaturized and simplified versions of organs that can be generated in vitro from differentiated cells, embryonic stem cells, induced pluripotent stem cells, or tumor cells. They can self-organize in a three-dimensional structure and are capable of self-renewal and replication. A milestone in the history of organoid cell development was the discovery in 2009 by Clevers and his group that Lgr5(+) stem cells can self-differentiate and form intestinal crypt structures containing all intestinal cell types. Subsequently, organoid research has expanded beyond normal tissue structures generated from stem cells to various solid tumors, such as pancreatic cancer, prostate cancer, breast cancer, and colorectal cancer. Tumor organoids can be used as substitutes for primary tumors in vitro, reproducing key aspects of their parental tumor composition, including tumor structure, heterogeneity, and function, and maintaining genetic stability during culture.

[0004] Clinically, to better treat bladder cancer, organoids are established using parental bladder tumors for screening anti-cancer drugs. Studies have shown that patient-derived organoids are considered the most promising in vitro models, retaining key characteristics of the parent tumor and allowing for large-scale drug screening, significantly reducing the limitations of clinical cancer treatment. However, the liquid culture medium currently used for culturing bladder tumor organoids does not enable rapid prototyping. Therefore, finding a way to rapidly prototyping bladder cancer organoids is urgently needed. Summary of the Invention

[0005] In view of this, the purpose of the present invention is to provide a bladder tumor organoid, its culture method and application. Using the culture method of the present invention, human bladder tumor organoids can be cultured, and bladder cancer organoids can be formed within 24 hours and primary cultured organoids can be obtained within 72 hours. The obtained human bladder tumor organoids can be digested and stably passaged.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0007] This invention provides a method for culturing bladder tumor organoids, comprising the following steps: mixing bladder tumor tissue with bladder tumor organoid culture medium to obtain a cell suspension; culturing the cell suspension in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids; wherein the bladder tumor organoid culture medium is based on Advanced DMEM / F-12 and further comprises HEPES buffer, penicillin-streptomycin solution, GlutaMAX, B-27 additive, N-acetylcysteine, nicotinamide, SB202190, A83-01, Y-27632, recombinant human Rspo1 protein, recombinant human cephaloprotein, recombinant human fibroblast growth factor-10, recombinant human fibroblast growth factor-2, human epidermal growth factor, and matrix gel.

[0008] Preferably, the pretreatment method for bladder tumor tissue includes the following steps: washing the bladder tumor tissue with PBS containing double antibodies and chopping it; washing and resuspending the chopped bladder tumor tissue in Advanced DMEM / F-12 medium containing Y-27632, filtering, centrifuging, and retaining the cell pellet; adding red blood cell lysis buffer to the cell pellet to remove red blood cells, thereby obtaining pretreated bladder tumor tissue.

[0009] Preferably, the bladder tumor organoid culture medium is based on Advanced DMEM / F-12 and further includes 0.5-2% HEPES buffer, 0.5-2% penicillin-streptomycin solution, 0.5-2% GlutaMAX, 1-3% B-27 additive, 0.5-2mM N-acetylcysteine, 8-12mM nicotinamide, 8-12μM MSB202190, 0.5-2μM MA83-01, 8-12μM MY-27632, 450-550 ng / mL recombinant human Rspo1 protein, 80-120 ng / mL recombinant human cephaloprotein, 15-25 ng / mL recombinant human fibroblast growth factor-10, 2-8 ng / mL recombinant human fibroblast growth factor-2, 45-55 ng / mL human epidermal growth factor, and 3-8% matrix gel.

[0010] Preferably, the cell number in the cell suspension is 0.2-1.8 × 10⁻⁶. 5 per mL.

[0011] Preferably, the culture conditions include: a temperature of 36.5-37.5°C, a carbon dioxide volume concentration of 4-6%, and a time of 48-72 h.

[0012] Preferably, the cultured bladder tumor organoids are digested and passaged, and the digestion solution used for digestion and passage is TrypLE Express containing Y-27632.

[0013] Preferably, the concentration of Y-27632 in the digestive fluid is 5-15 μM.

[0014] Preferably, the digestion and subculture conditions include: water bath digestion at 36.5-37.5℃ for 10-15 minutes.

[0015] This invention provides bladder tumor organoids obtained by the culture method described above.

[0016] This invention provides bladder tumor organoids obtained by the culture method described above, or the application of the bladder tumor organoids in constructing bladder cancer models or drug screening.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The culture method described in this invention enables rapid culture of human bladder tumor organoids, improving the success rate. Furthermore, this method optimizes the culture environment for bladder tumor cells, minimizing damage to the tumor organoids and significantly preserving their viability and proliferative capacity after passage, thus meeting the requirements for long-term bladder tumor organoid culture. Organoids can be cultured within 24 hours, and primary cultured organoids can be obtained within 72 hours. Moreover, the bladder tumor organoids cultured using this method can be digested and stably passaged. This method is applicable to currently used organoid culture conditions.

[0019] Furthermore, this invention also provides a culture medium for human bladder tumor organoids, based on AdvancedDMEM / F-12, and further comprising HEPES buffer, penicillin-streptomycin solution, GlutaMAX, B-27 additive, N-acetylcysteine, nicotinamide, SB202190, A83-01, Y-27632, recombinant human Rspo1 protein, recombinant human cephaloprotein, recombinant human fibroblast growth factor-10, recombinant human fibroblast growth factor-2, human epidermal growth factor, and matrix gel. The use of these components in combination ensures stable and efficient formation and growth of bladder tumor organoids. The cultured bladder tumor organoids can form within 24 hours, and the organoid growth rate is faster, the culture efficiency is higher, and the use of cytokines is reduced, making it more economical.

[0020] Furthermore, the culture method using the culture medium and ultra-low adsorption cell culture plate described in this invention has lower operational requirements for the implementer, is more convenient to operate, and does not require frequent replacement of the culture medium during the culture period; only periodic replenishment of the culture medium is needed to meet the requirements. Attached Figure Description

[0021] Figure 1 Bright-field image of human bladder tumor organoids cultured for 24 hours in Example 1, scale bar 100 μm.

[0022] Figure 2 Bright-field image of human bladder tumor organoids cultured for 48 hours in Example 1, scale bar 100 μm.

[0023] Figure 3 Bright-field image of human bladder tumor organoids cultured for 1 week in Example 1, scale bar 100 μm.

[0024] Figure 4 Bright-field image of human bladder tumor organoids after 24 hours of culture, Comparative Example 1. Scale bar is 100 μm.

[0025] Figure 5 Bright-field image of human bladder tumor organoids cultured for 48 hours as Comparative Example 1. Scale bar is 100 μm.

[0026] Figure 6 Bright-field image of human bladder tumor organoids after 1 week of culture, Comparative Example 1. Scale bar is 100 μm.

[0027] Figure 7 This is an immediate bright-field image after digestion in Example 1, with a scale bar of 100 μm.

[0028] Figure 8 This is a bright-field image of Example 1 after culturing in an ultra-low adsorption 384-well plate for 24 hours. The scale bar is 100 μm.

[0029] Figure 9 Bright-field image of human bladder tumor organoids cultured for 48 hours in Example 2, scale bar 100 μm.

[0030] Figure 10 Bright-field images of human bladder tumor organoids cultured for 48 hours for Comparative Example 2 are shown, with a scale bar of 100 μm.

[0031] Figure 11 Image of primary tumor tissue stained with hematoxylin and eosin (HE), scale bar 100 μm.

[0032] Figure 12 HE staining image of bladder tumor organoids cultured in Example 1, scale bar is 100 μm. Detailed Implementation

[0033] This invention provides a method for culturing bladder tumor organoids, comprising the following steps: mixing bladder tumor tissue with human bladder tumor organoid culture medium to obtain a cell suspension; culturing the cell suspension in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids; wherein the bladder tumor organoid culture medium is based on Advanced DMEM / F-12 and further includes HEPES buffer, penicillin-streptomycin solution, GlutaMAX, B-27 additive, N-acetylcysteine, nicotinamide, SB202190, A83-01, Y-27632, recombinant human Rspo1 protein, recombinant human cephaloprotein, recombinant human fibroblast growth factor-10, recombinant human fibroblast growth factor-2, human epidermal growth factor, and matrix gel. This invention uses an ultra-low adsorption cell culture plate to suspend and culture bladder tumor organoids in liquid culture medium. The method of culturing using the aforementioned bladder tumor organoid culture medium and ultra-low adsorption cell culture plate allows bladder cancer organoids to form within 24 hours. The ultra-low adsorption cell culture plate of this invention is preferably an ultra-low adsorption 24-well plate.

[0034] In this invention, the pretreatment method for bladder tumor tissue includes the following steps: washing the bladder tumor tissue with PBS containing antibiotics and mincing it; washing and resuspending the minced bladder tumor tissue in Advanced DMEM / F-12 medium containing Y-27632 (the concentration of Y-27632 in this medium is 8-12 μM), filtering, centrifuging, and retaining the cell pellet; adding red blood cell lysis buffer to the cell pellet to remove red blood cells, obtaining the pretreated bladder tumor tissue. This invention minces the bladder tumor tissue to less than 1 mm. 3 This invention uses a 60-80 μm cell filter and centrifuges at 250-350 × g for 2-8 min. The residual tissue on the cell filter is then enzymatically digested in 8-12 mL of Advanced DMEM / F-12 medium containing collagenase II and Y-27632 (the concentration of collagenase II in this medium is 2-6 mg / mL, and the concentration of Y-27632 is 8-12 μM). Digestion is performed at 35-38℃ for 25-38 min, with pipetting every 8-12 min. The mixture is then filtered through a 60-80 μm cell filter, centrifuged at 250-350 × g for 2-8 min, the supernatant is discarded, and the cell pellet is retained.

[0035] In this invention, the bladder tumor organoid culture medium is based on Advanced DMEM / F-12, and preferably includes 0.5-2% HEPES buffer, 0.5-2% penicillin-streptomycin solution, 0.5-2% GlutaMAX, 1-3% B-27 additive, 0.5-2mM N-acetylcysteine, 8-12mM nicotinamide, 8-12μM SB202190, 0.5-2μM A83-01, and 8-12μM... Y-27632, 450-550 ng / mL recombinant human Rspo1 protein, 80-120 ng / mL recombinant human cephaloprotein, 15-25 ng / mL recombinant human fibroblast growth factor-10, 2-8 ng / mL recombinant human fibroblast growth factor-2, 45-55 ng / mL human epidermal growth factor, and 3-8% matrix gel; further preferably including 1% HEPES buffer, 1% penicillin-streptomycin solution, 1% GlutaMAX, 2% B-27 additive, 1 mM N-acetylcysteine, 10 mM nicotinamide, 10 μM SB202190, 1 μM MA83-01, 10 μM MY-27632, 500 ng / mL recombinant human Rspo1 protein, 100 ng / mL recombinant human cephaloprotein, 20 ng / mL recombinant human fibroblast growth factor-10, 5 ng / mL recombinant human fibroblast growth factor-2, 50 ng / mL human epidermal growth factor, and 5% matrix gel. The percentages (%) mentioned in this invention refer to volume percentages. The mM, μM, and ng / mL mentioned in this invention refer to final concentrations.

[0036] In this invention, the HEPES buffer maintains the culture medium in a neutral state suitable for cell growth; GlutaMAX significantly reduces the accumulation of toxic ammonia in cells and culture medium, improving cell viability and growth; the recombinant human Rspo1 protein maintains the stemness of bladder tumor organoids; nicotinamide, an amide compound of nicotinic acid, plays a role in protein and sugar metabolism, promoting organoid formation and prolonging organoid lifespan; N-acetylcysteine ​​is a ROS inhibitor with antioxidant activity; the B-27 additive maintains organoid growth; A83-01 is an Activin / NODAL / TGF-beta pathway inhibitor, inhibiting kinases such as ALK5, ALK4, and ALK7 to maintain cell activity and proliferation; and human epidermal growth factor promotes the growth of epidermal or epithelial cells. Y27632 is a potent inhibitor of ROCK, which can inhibit stem cell apoptosis; the recombinant human cephalin binds to ligands of the TGF-α family and regulates their activity by inhibiting their acquisition of signal transduction receptors, and antagonizes BMP activity to promote stem cell proliferation while maintaining their undifferentiated state; the recombinant human fibroblast growth factor-2, also known as basic FGF (bFGF), as a ligand of FGFR1, FGFR2, FGFR3 and FGFR4, plays an important role in the regulation of cell survival, division, differentiation and migration, and is a key mitogen in cancer, regulating the self-renewal of various stem cell types; the recombinant human fibroblast growth factor-10 is also a member of the fibroblast growth factor family, with broad mitotic and cell survival-promoting activities, and participates in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. Meanwhile, the culture medium described in this invention also optimizes the amount of matrix gel used; the combination of the above components in this invention ensures the stable and efficient formation and growth of bladder tumor organoids. The cultured bladder tumor organoids can be formed within 24 hours, and the organoids have a faster growth rate and higher culture efficiency. It also reduces the use of cytokines and is more economical.

[0037] In this invention, the cell number in the cell suspension is 0.2-1.8 × 10⁻⁶. 5 Cells / mL, preferably 0.5-1.5×10⁻⁶. 5 Cells / mL, more preferably 1×10⁻⁶ 5 Cells / mL. The cell count in the cell suspension described in this invention refers to the amount of single cells and small cell clusters.

[0038] In this invention, the culture conditions include: a temperature of 36.5-37.5°C, a carbon dioxide volume concentration of 4-6%, and a time of 48-72 hours; the preferred culture conditions include: a temperature of 37°C and a carbon dioxide volume concentration of 5%.

[0039] In this invention, the cultured bladder tumor organoids are digested and passaged. The digestion solution used for passage is TrypLE Express containing Y-27632. The concentration of Y-27632 in the digestion solution is 5-15 μM, preferably 8-12 μM, and more preferably 10 μM. The conditions for passage include digestion in a water bath at 36.5-37.5℃ for 10-15 min; the preferred conditions include digestion in a water bath at 37℃ for 10-15 min, with the cells being pipetted every 5 min. After digestion, the cells are diluted with excess PBS to terminate the digestion, centrifuged at 250-350×g for 2-8 min, and the cell pellet is retained. The pellet is resuspended in the bladder tumor organoid culture medium to obtain a cell suspension and is counted. Then, the digested bladder tumor single cells are cultured at 1-4×10⁶ cells per well. 5 Cells / mL are seeded onto 24-well ultra-low adsorption cell culture plates for further culture, cryopreservation, or drug sensitivity testing.

[0040] The present invention also provides bladder tumor organoids obtained by the culture method described above.

[0041] The present invention also provides bladder tumor organoids obtained by the culture method described above, or the application of the bladder tumor organoids described above in the construction of bladder cancer models or drug screening.

[0042] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0043] The reagents and materials used in the embodiments of this invention can all be purchased from the market. The reagents, materials and their sources used in this invention are shown in Table 1.

[0044] Table 1. Sources of reagents and materials

[0045]

[0046]

[0047] Example 1

[0048] 1. The components and final concentrations or volumes of the bladder tumor organoid culture medium used in this embodiment are shown in Table 2.

[0049] Table 2. Detailed information on human bladder tumor organoid culture media.

[0050] Element Final concentration / volume percentage AdvancedDMEM / F-12 - Penicillin-Streptomycin Solution (Antibiotic-Antimycotic 100×) 1% GlutaMAX(100×) 1% HEPES buffer (HEPES (pH 7.4) 100×) 1% B-27 Additive (B-27 Supplement 50×) 2% N-Acetylcysteine 1mM Nicotinamide 10mM SB202190 10μM A83-01 1μM Y-27632 10μM Recombinant human R-spondin 1 protein 500ng / mL Recombinant human cephalin (Humannoggin) 100ng / mL Recombinant human FGF-10 20ng / mL Recombinant human FGF-2 5ng / mL Human Epidermal Growth Factor (Human EGF) 50 ng / mL Matrigel 5%

[0051] Note: The penicillin-streptomycin solution (Antibiotic-Antimycotic 100×), GlutaMAX (100×), HEPES buffer (HEPES (pH 7.4) 100×) and B-27 supplement (B-27 Supplement 50×) should be diluted to 1× before use. That is, the volume percentage of penicillin-streptomycin solution (Antibiotic-Antimycotic 1×), GlutaMAX 1×, and HEPES buffer (HEPES (pH 7.4) 1×) is 1%, and the volume percentage of B-27 supplement (B-27 Supplement 1×) is 2%.

[0052] 2. The culture method for human bladder tumor organoids, and the specific operation steps are as follows:

[0053] (1) The bladder tumor tissue sample A obtained clinically (approved by the ethics committee) was stored at 4°C in fetal bovine serum containing Y-27632 (the concentration of Y-27632 in the fetal bovine serum was 10 μM) and transferred to the laboratory at low temperature within 24 hours.

[0054] (2) Wash the bladder tumor tissue with PBS containing double antibodies 3-5 times, then mince the bladder tumor tissue to less than 1 mm. 3 size.

[0055] (3) The bladder tumor tissue was washed and resuspended in Advanced DMEM / F-12 medium containing Y-27632 (the concentration of Y-27632 in the medium was 10 μM), repeatedly pipetted for 5-10 min, filtered through a 70 μm cell filter, centrifuged at 300×g for 5 min, the supernatant was removed, and the cell pellet I was retained.

[0056] The remaining tissue on the cell filter was enzymatically digested in 10 mL of Advanced DMEM / F-12 medium containing collagenase II and Y-27632 (the concentration of collagenase II in this medium is 4 mg / mL and the concentration of Y-27632 is 10 μM). The digestion was carried out at 37°C for 30 min, with the mixture being pipetted every 10 min. The mixture was then filtered through a 70 μm cell filter, centrifuged at 300 × g for 5 min, and the supernatant was discarded, while cell pellet II was retained.

[0057] Cell pellets I and II were added to red blood cell lysis buffer to remove red blood cells, resulting in pretreated bladder tumor tissue.

[0058] (4) Bladder tumor organoid culture medium (Table 2) was added to the pretreated bladder tumor tissue to obtain a cell suspension and single cells and cell clusters were counted;

[0059] Single cells and cell clusters were divided into groups of 1×10.5 Cells / mL were seeded into 24-well plates with ultra-low adsorption and incubated in a cell incubator at 37°C with a carbon dioxide concentration of 5% (V / V).

[0060] For long-term culture, the culture medium for bladder tumor organoids can be supplemented every 3 days during the culture period (Table 2).

[0061] 3. The specific steps for digestion and passage culture of bladder tumor organoids are as follows:

[0062] (1) Collect bladder tumor organoids cultured for 72 hours or longer in step (2): To avoid reducing mechanical damage to bladder tumor organoids, use a pipette with the tip cut off to gently transfer the bladder tumor organoids into centrifuge tubes, centrifuge at 300×g for 5 minutes, and retain the organoid precipitate.

[0063] (2) The organoid precipitate obtained after centrifugation was resuspended in 5 mL of TrypLE Express containing Y-27632 (the concentration of Y-27632 in TrypLE Express was 10 μM) and digested in a water bath at 37°C for 10-15 min, with the tubes being blown every 5 min.

[0064] (3) After digestion, add excess PBS to dilute and stop digestion. Centrifuge at 300×g for 5min and retain the cell pellet. Add bladder tumor organoid culture medium (Table 2) to resuspend the cell suspension and count the cells.

[0065] (4) Digested tumor single cells were distributed at 1-4 × 10⁻⁴ per well. 5 Cells / mL are seeded onto 24-well ultra-low adsorption cell culture plates for further culture, cryopreservation, or drug sensitivity testing.

[0066] Example 2

[0067] Human bladder tumor organoids were obtained by culturing clinically obtained bladder tumor tissue sample B (approved by the ethics committee), and the culture medium and other steps were the same as in Example 1.

[0068] Comparative Example 1

[0069] The specific steps for culturing human bladder tumor organoids are as follows:

[0070] (1) Thaw the substrate gel to be used on ice in advance, and keep the untreated 24-well plate to be used at 37°C for 4 hours in advance.

[0071] (2) The bladder tumor tissue sample A obtained clinically was stored at 4°C in fetal bovine serum containing Y-27632 (the concentration of Y-27632 in the fetal bovine serum was 10 μM) and transferred to the laboratory at low temperature within 24 hours.

[0072] (3) The steps for obtaining bladder tumor tissue after pretreatment are the same as in Example 1.

[0073] (4) Bladder tumor organoid culture medium (Table 2) was added to the pretreated bladder tumor tissue to obtain a cell suspension and single cells and cell clusters were counted;

[0074] Take 10 μL of cell suspension per well of a 24-well plate (5-7 × 10⁶ cells / well). 5 Mix (number / mL) with 50 μL of thawed matrix gel on ice;

[0075] Prepare an untreated 24-well plate and place it on a low-temperature heating pad. Use a pipette to slowly drop 50 μL of matrix gel mixed with cell suspension into the center of the 24-well plate and keep it on the low-temperature heating pad for a period of time.

[0076] Once the matrix gel droplets have solidified slightly, transfer the 24-well plate to a cell incubator for 30 minutes to allow the matrix gel to solidify further. Then, slowly add bladder tumor organoid culture medium along the well wall. The composition of this culture medium is as shown in Table 2, excluding Matrigel.

[0077] The culture medium used for culturing bladder tumor organoids was changed every 3 days during the culture period (Table 2).

[0078] Comparative Example 2

[0079] The method for culturing human bladder tumor organoids differs from that in Example 2 in that the recombinant human Rspo1 protein and recombinant human cephaloprotein are removed from the culture medium components in Table 2, while the remaining components and amounts are the same; the experimental steps are the same as in Example 2.

[0080] Experimental Example 1

[0081] The specific steps for drug sensitivity testing of bladder tumor organoids are as follows:

[0082] (1) The first-generation bladder tumor organoids cultured for 72 hours in step 2 of Example 1 were digested and passaged in step 3 to obtain dissociated single cells. The cells were resuspended in bladder tumor organoid culture medium (Table 2) and counted. Comparative Example 1 was treated in the same way.

[0083] (2) Using a single-cell count concentration of 4-5 × 10 5 The cells were seeded in a 384-well plate with an ultra-low adsorption black transparent bottom, with 20 μL per well, which means each well contains 8000-10000 single cells. The cells were then incubated in a cell incubator.

[0084] (3) After 24 hours of culture, bladder tumor organoids were observed to form. One antitumor drug was added to each well. The antitumor drugs were cisplatin, gemcitabine, cisplatin + gemcitabine, paclitaxel, docetaxel, methotrexate, doxorubicin, vincristine, daunorubicin, and epirubicin. 20 μL of each antitumor drug was added to each well. Each treatment was performed in 3 parallel experiments. Water and DMSO were used as negative controls. Each treatment was performed in 5 parallel experiments. The cells were then placed in a cell incubator for culture.

[0085] (4) After the culture is treated with the required drugs for a certain period of time, add 40 μL of CellTiter-Glo 3D detection reagent and mix thoroughly for 5 min to lyse the bladder tumor organoids. Then incubate the culture plate at room temperature for another 25 min to stabilize the luminescence signal. Use an ELISA reader that can record the luminescence signal to detect the luminescence value and process the data. The luminescence value is directly proportional to the amount of ATP in the cells, and the amount of ATP is directly proportional to the number of live cells in the culture. This can confirm the sensitivity of bladder tumor organoids to various anti-tumor drugs.

[0086] The mean (μ) and standard deviation (σ) of the luminescence values ​​of the control group and the mean (x) of the luminescence values ​​of each experimental group were calculated. The Z-score was calculated as (x-μ) / σ, with a larger absolute Z-score indicating a greater difference from the control group. Standardized Z-score calculations allow for a unified comparison of the sensitivity of different samples to drug responses. The results are shown in Tables 3 and 4, demonstrating that the bladder tumor organoids constructed using this method are well-suited for drug sensitivity testing.

[0087] Table 3. Sensitivity to different drugs

[0088]

[0089] Table 4. Sensitivity of negative control drugs

[0090]

[0091] Experiment Example 2

[0092] 1. Images were taken of the human bladder tumor organoids cultured in Example 1 and Comparative Example 1 after 24 hours, 48 ​​hours, and 1 week; immediately after cell digestion in Example 1; and after 24 hours of culture in an ultra-low adsorption black transparent 384-well plate in Experimental Example 1. The results are as follows: Figures 1-8 As shown.

[0093] Depend on Figures 1-6It can be seen that, under the same culture time conditions, the diameters of the tumor organoids obtained by the culture method in Example 1 and the culture method in Comparative Example 1 are different. The diameter of the tumor organoids obtained by the culture method in Example 1 is significantly larger than that obtained by the culture method in Comparative Example 1, and the tumor organoids obtained by the culture method in Example 1 can form within 24 hours; Figure 7 It can be seen that single cells can be obtained after digestion in Example 1. Figure 8 It can be seen that culturing in an ultra-low adsorption 384-well plate for 24 hours can meet the requirements for drug detection.

[0094] 2. After digestion of the tissues from Example 2 and Comparative Example 2, the same cell concentration of 1×10⁻⁶ was used. 5 All samples were plated and observed using an inverted microscope at 10x magnification after 48 hours of incubation. Once the field of view was determined, a camera was connected to the microscope, and photographs were taken while ensuring sharp focus. Results are as follows: Figure 9-10 The results showed that the bladder tumor organoid culture medium of the present invention produced cells of more uniform size, and the cell growth size demonstrated the necessity of the two cytokines for the growth of bladder tumor organoids.

[0095] 3. HE staining of bladder tumor organoids and original tumor tissue sections cultured for 72 hours in Example 1. HE staining procedure: Prepare original tumor tissue sections and bladder tumor organoid sections, dewax to remove paraffin, then hydrate, gradually immerse the sections in alcohols of different concentrations, and finally wash with distilled water. Then, immerse the sections sequentially in hematoxylin solution and eosin solution, rinse again, dehydrate, and prepare slides for observation. Results are as follows: Figure 11-12 The results showed that the bladder tumor organoids cultured in this invention were identical to the original tumor tissue.

[0096] Therefore, the use of the second-generation tumor organoids cultured by digestion in the culture method described in this invention can shorten the time for obtaining drug sensitivity data. In practical applications, relevant bladder tumor sensitivity data to various anti-tumor drugs can be obtained within one week of obtaining clinical patient tissue samples. Multiple drugs can also be tested in a relatively short time, greatly advancing the possibility of translating basic research into clinical applications and providing timely reference and basis for clinical decision-making and treatment selection.

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for culturing bladder tumor organoids, characterized in that, The steps include: Bladder tumor tissue was mixed with bladder tumor organoid culture medium to obtain a cell suspension. The cell suspension was then cultured in an ultra-low adsorption cell culture plate to obtain bladder tumor organoids. The bladder tumor organoid culture medium is based on Advanced DMEM / F-12 and also includes 0.5-2% HEPES buffer, 0.5-2% penicillin-streptomycin solution, 0.5-2% GlutaMAX, 1-3% B-27 additive, 0.5-2mM acetylcysteine, 8-12mM nicotinamide, 8-12μM SB202190, 0.5-2μM A83-01, 8-12μM Y-27632, 450-550ng / mL recombinant human Rspo1 protein, 80-120ng / mL recombinant human cephaloprotein, 15-25ng / mL recombinant human fibroblast growth factor-10, 2-8ng / mL recombinant human fibroblast growth factor-2, 45-55ng / mL human epidermal growth factor, and 3-8% matrix gel. The pretreatment method for bladder tumor tissue includes the following steps: washing the bladder tumor tissue with PBS containing double antibodies and mincing it; washing and resuspending the minced bladder tumor tissue in Advanced DMEM / F-12 medium containing Y-27632, filtering, centrifuging, and retaining the cell pellet; adding red blood cell lysis buffer to the cell pellet to remove red blood cells, thereby obtaining the pretreated bladder tumor tissue. The cell suspension contained 0.2-1.8 × 10⁻⁶ cells. 5 per mL.

2. The cultivation method according to claim 1, characterized in that, The culture conditions include: temperature 36.5-37.5℃, carbon dioxide volume concentration 4-6%, and time 48-72h.

3. The cultivation method according to claim 1, characterized in that, The bladder tumor organoids obtained from the culture were digested and passaged. The digestion solution used for the digestion and passage was TrypLE Express containing Y-27632.

4. The cultivation method according to claim 3, characterized in that, The concentration of Y-27632 in the digestive fluid is 5-15 μM.

5. The cultivation method according to claim 3, characterized in that, The conditions for digestion and subculture include: digestion in a water bath at 36.5-37.5℃ for 10-15 minutes.

Citation Information

Patent Citations

  • Liver cancer organoid and culture method, culture medium and application of organoid

    CN112210537A

  • Bladder cancer organoid culture medium and culture method

    CN112522201A

  • Efficient modeling and vascularization method for small intestine organoids

    CN117535226A

  • Thymus tumor organoid construction method and culture solution thereof

    CN118834829A